** Shares in Straumann STMN.S are seen up 3.2% pre-market after the Swiss dental implants maker beat Q1 sales expectations as its business in China stabilizes
** Revenue declined to 673 million Swiss francs ($853 million) in Q1, down 1.2% yoy but up 7.1% when adjusted for currency effects. That beat analysts' average forecast of 665.5 million francs, according to data from Vara
** J.P.Morgan says the results are good enough in the near term for a mid-single-digit bounce
** Vontobel says underlying trends in China are stabilizing with improving patient flow and distributors slowly restocking from low inventory levels
** Jefferies adds that China stabilization should also offer upside to H1 margin
** Up to the previous session's close, shares were down 10.4% YTD
(Reporting by Bartosz Dabrowski in Gdansk)
((bartosz.dabrowski@thomsonreuters.com; +48 58 7696560;))